Corey Manley Sells 5,025 Shares of Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc. (NASDAQ:OMCL) EVP Corey Manley sold 5,025 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the transaction, the executive vice president owned 112,783 shares in the company, valued at approximately $4,874,481.26. This represents a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Omnicell Stock Up 1.4%

Shares of NASDAQ OMCL traded up $0.60 during midday trading on Tuesday, reaching $43.82. 436,978 shares of the company’s stock traded hands, compared to its average volume of 625,535. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. The stock’s 50 day simple moving average is $37.66 and its 200-day simple moving average is $40.50. Omnicell, Inc. has a one year low of $26.84 and a one year high of $55.00. The company has a market cap of $1.99 billion, a price-to-earnings ratio of 99.59, a P/E/G ratio of 1.12 and a beta of 0.96.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The firm had revenue of $309.88 million for the quarter, compared to the consensus estimate of $304.02 million. During the same period last year, the firm earned $0.26 earnings per share. The company’s quarterly revenue was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, analysts predict that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Omnicell

Several institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in Omnicell by 6.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock valued at $81,791,000 after acquiring an additional 137,834 shares in the last quarter. Wellington Management Group LLP boosted its stake in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after acquiring an additional 1,265,818 shares in the last quarter. Lazard Asset Management LLC boosted its stake in Omnicell by 3.8% in the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after acquiring an additional 62,733 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in Omnicell by 2.0% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock valued at $47,095,000 after acquiring an additional 27,497 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Omnicell by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock worth $51,088,000 after buying an additional 11,424 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

OMCL has been the topic of a number of recent research reports. Piper Sandler reiterated an “overweight” rating and set a $49.00 price objective (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price objective on the stock in a research note on Wednesday, February 4th. KeyCorp increased their price objective on shares of Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Craig Hallum reiterated a “buy” rating and set a $55.00 price objective on shares of Omnicell in a research note on Wednesday, April 29th. Finally, Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $59.86.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.